GLENN SCHWARCZ: Open Payments
NPI 1952481996 · MONSEY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$784 in 31 payments from 11 companies in 2025. Trend: 2023 $827 · 2024 $240 · 2025 $784
Food & beverage: $784
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $249 |
| Alkermes, Inc. | 4 | $102 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| E.R. Squibb & Sons, L.L.C. | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 2 | $58 |
| Lundbeck LLC | 2 | $54 |
| Biogen, Inc. | 2 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
Products named: VRAYLAR, ARISTADA, ABILIFY MAINTENA, REXULTI, COBENFY, AUSTEDO XR, ZURZUVAE, CAPLYTA.
Industry payments across NY — which companies pay providers there.
